Chardan Capital analyst Gbola Amusa reiterated a Buy rating on RegenXBio (RGNX) today and set a price target of $127.50. The company’s shares closed yesterday at $45.68.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 13.2% and a 45.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Voyager Therapeutics Inc.
RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $98.63.
See today’s analyst top recommended stocks >>
RegenXBio’s market cap is currently $1.63B and has a P/E ratio of 20.17. The company has a Price to Book ratio of 3.30.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RGNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
